Comparative Pharmacology
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus WEGOVY.
EXENATIDE SYNTHETIC vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category A/B
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist